Cure8 research brief
Fecal calprotectin rises, even without symptoms, may flag a higher short-term relapse risk in UC patients maintained on 5-ASA alone. That could support more proactive monitoring or consideration of treatment changes for a subset of patients.
Adult UC patients on 5-ASA/mesalamine monotherapy, gastroenterologists/IBD clinicians, and researchers focused on biomarkers for relapse prediction.
The authors analyzed 20 patients in clinical remission on stable 5-ASA therapy who had an FCP increase from ≤142 µg/g to above that threshold. Four patients (20%) relapsed within 6 months. Median FCP at the time of elevation was higher in those who relapsed (533 µg/g) than those who did not (219 µg/g).
An exploratory ROC analysis suggested an optimal cutoff around 491 µg/g (AUC 0.828), but this is preliminary given the small sample size.
Small retrospective study (n=20) with exploratory analyses. Assay-specific thresholds were used; external validation is needed before adopting the reported cutoff (491 µg/g) clinically.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
